Case studies showing clinical signs and management of cutaneous toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours

Authors

  • Ingrid M. E. Desar Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
  • H. Jorn Bovenschen Department of Dermatology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
  • Anja J. N. H. Timmer-Bonte Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; Department of Pulmonary Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
  • Mireille V. Cantarini AstraZeneca, Alderley Park, UK
  • Winette T. A. van der Graaf Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
  • Michelle M. van Rossum Department of Dermatology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
  • Carla M. L. van Herpen Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

DOI:

https://doi.org/10.3109/02841860903104152

Abstract

No abstract available

Downloads

Download data is not yet available.

Downloads

Published

2010-01-01

How to Cite

Desar, I. M. E., Bovenschen, H. J., Timmer-Bonte, A. J. N. H., Cantarini, M. V., van der Graaf, W. T. A., van Rossum, M. M., & van Herpen, C. M. L. (2010). Case studies showing clinical signs and management of cutaneous toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours. Acta Oncologica, 49(1), 113–116. https://doi.org/10.3109/02841860903104152

Issue

Vol. 49 No. 1 (2010): Acta Oncologica

Section

Articles